keyword
MENU ▼
Read by QxMD icon Read
search

vedolizumab crohn's

keyword
https://www.readbyqxmd.com/read/28333288/exposure-efficacy-relationships-for-vedolizumab-induction-therapy-in-patients-with-ulcerative-colitis-or-crohn-s-disease
#1
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Huyuan Yang, Silvio Danese, Jean-Frédéric Colombel, Michael Smyth, William J Sandborn, Brian G Feagan, Walter Reinisch, Bruce E Sands, Miguel Sans, Irving Fox
Background and Aims: A positive relationship between vedolizumab trough serum concentrations and clinical outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) has been reported. Here we further explore exposure-efficacy relationships for vedolizumab induction therapy in post hoc analyses of GEMINI study data. Methods: Vedolizumab trough concentrations at Week 6 or 10 were grouped in quartiles and clinical outcome rates calculated. Exposure-efficacy relationships at Week 6 and potential baseline covariate effects were explored using logistic regression and individual predicted cumulative average concentration through Week 6 (Caverage) as exposure measure...
February 17, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28326566/systematic-review-with-meta-analysis-comparative-efficacy-of-biologics-for-induction-and-maintenance-of-mucosal-healing-in-crohn-s-disease-and-ulcerative-colitis-controlled-trials
#2
REVIEW
A Cholapranee, G S Hazlewood, G G Kaplan, L Peyrin-Biroulet, A N Ananthakrishnan
BACKGROUND: Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. AIM: To perform a systematic review and meta-analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. METHODS: We performed a systematic review and meta-analysis of randomised controlled trials (RCT) examining mucosal healing as an endpoint of immunosuppressives, anti-tumour necrosis factor α (anti-TNF) or anti-integrin monoclonal antibody therapy for moderate-to-severe CD or UC...
March 22, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28247573/review-article-moving-towards-common-therapeutic-goals-in-crohn-s-disease-and-rheumatoid-arthritis
#3
REVIEW
P B Allen, P Olivera, P Emery, D Moulin, J-Y Jouzeau, P Netter, S Danese, B Feagan, W J Sandborn, L Peyrin-Biroulet
BACKGROUND: Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability. AIM: To review the similarities and differences in treatment goals between CD and rheumatoid arthritis...
March 1, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28221249/the-%C3%AE-4%C3%AE-1-homing-pathway-is-essential-for-ileal-homing-of-crohn-s-disease-effector-t-cells-in-vivo
#4
Sebastian Zundler, Anika Fischer, Daniela Schillinger, Marie-Theres Binder, Raja Atreya, Timo Rath, Rocío Lopez-Pósadas, Caroline J Voskens, Alastair Watson, Imke Atreya, Clemens Neufert, Markus F Neurath
BACKGROUND: The precise mechanisms controlling homing of T effector (Teff) cells to the inflamed gut in Crohn's disease (CD) are still unclear, and clinical outcome data from patients with inflammatory bowel disease treated with the anti-α4β7 integrin antibody vedolizumab suggest differences between ulcerative colitis and CD. METHODS: Expression of homing molecules was studied with flow cytometry and immunohistochemistry. Their functional role was investigated in in vitro adhesion assays and in a humanized mouse model of T cell homing to the inflamed gut in vivo...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28204866/vedolizumab-treatment-for-immune-checkpoint-inhibitor-induced-enterocolitis
#5
Viktoria Bergqvist, Erik Hertervig, Peter Gedeon, Marija Kopljar, Håkan Griph, Sara Kinhult, Ana Carneiro, Jan Marsal
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selective activation of the immune system, immune-related adverse events (irAEs) are frequent. Enterocolitis is a common irAE, currently managed with corticosteroids and, if necessary, anti-tumor necrosis factor-α therapy...
February 15, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28178003/efficacy-and-safety-of-vedolizumab-for-induction-of-remission-in-inflammatory-bowel-disease-the-israeli-real-world-experience
#6
Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar-Gil Shitrit, Eran Israeli, Doron Schwartz, Eran Zittan, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan
BACKGROUND: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the "real world" efficacy and safety of VDZ in a large national patient cohort. METHODS: Patients with inflammatory bowel disease treated with VDZ were prospectively followed for 14 weeks. Patients who completed the induction protocol (week 0/2/6/14) or discontinued the treatment before week 14 for adverse events (AEs) or primary nonresponse were included...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28175096/p445-perioperative-use-of-vedolizumab-seems-not-associated-with-short-term-postoperative-infectious-complications-in-patients-with-crohn-s-disease-undergoing-right-hemicolectomy-with-ileocolonic-anastomosis
#7
N Schils, A De Buck van Overstraeten, S Vermeire, G Van Assche, A Wolthuis, A D'Hoore, M Ferrante
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175093/p501-baseline-characteristics-of-crohn-s-disease-patients-in-the-vedolizumab-pass-study-a-cohort-study-assessing-the-safety-and-effectiveness-of-vedolizumab-compared-to-other-biologic-agents-02
#8
C A Siegel, G Lichtenstein, B Siegmund, J D Lewis, D Wolf, E Louis, S Sebastian, X Hebuterne, A Bell, C Söderman, S Schubert, R Atreya, S Polyak, S Hoque, A Krummenerl, B Bokemeyer, T Krummenerl, S Shulmann, P Karlén, B Moum, P Dolin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172955/p447-vedolizumab-induces-significantly-higher-endoscopic-remission-rates-at-week-16-in-ulcerative-colitis-as-compared-to-crohn-s-disease
#9
R W M Pauwels, A C De Vries, C J Van der Woude
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172925/p391-differential-use-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-real-life-results-from-2-tertiary-referral-centres-in-the-united-kingdom
#10
N Kamperidis, A Cavazza, M Wahed, N Arebi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172887/p416-real-world-data-on-the-effectiveness-and-safety-of-vedolizumab-in-the-treatment-of-crohn-s-disease-and-ulcerative-colitis-the-edinburgh-experience
#11
N Plevris, T A Manship, A Deekae, G R Jones, C L Noble, J Satsangi, A G Shand, I D Arnott, C W Lees
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172706/dop021-long-term-effectiveness-and-safety-of-vedolizumab-in-patients-with-crohn-s-disease-5-year-cumulative-exposure-of-gemini-2-completers-rolling-into-the-gemini-open-label-extension-study
#12
S Vermeire, E V Loftus, J-F Colombel, B Feagan, W Sandborn, B Sands, S Danese, G D'Haens, A Kaser, R Panaccione, D Rubin, I Shafran, S O'Byrne, P Geransar, A Previtali, J M Khalid, A Kaviya
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172674/p531-discontinuation-of-corticosteroids-among-crohn-s-disease-patients-treated-with-vedolizumab-in-the-united-states
#13
H Patel, B Chastek, K D Null, D Demuth
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172630/dop019-effect-of-vedolizumab-treatment-on-extraintestinal-manifestations-in-patients-with-crohn-s-disease-a%C3%A2-gemini-2-post-hoc-analysis
#14
B G Feagan, W J Sandborn, J-F Colombel, S O'Byrne, J M Khalid, N Brayshaw, P Geransar, D T Rubin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172459/p305-indirect-comparison-of-two-novel-biologics-for-the-treatment-of-crohn-s-disease-network-meta-analysis-of-ustekinumab-vs-vedolizumab
#15
G Hather, R Curtis, K Minda, I A Zouraq, J M Khalid
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172422/dop020-higher-vedolizumab-levels-are-associated-with-deep-remission-in-patients-with-crohn-s-disease-and-ulcerative-colitis-on-maintenance-therapy-with-vedolizumab
#16
A Yarur, A Bruss, A Jain, V Kondragunta, K Hester, T Luna, D Agrawal, A Patel, C Fox, S Werner, S Naik, D Stein
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172395/op020-recent-anti-tnf-exposure-predicts-lower-vedolizumab-trough-concentrations-in-patients-with-crohn-s-disease
#17
A Gils, E Dreesen, G Compernolle, M Peeters, E Brouwers, S Tops, V Ballet, M Noman, M Ferrante, G Van Assche, S Vermeire
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28169436/vedolizumab-exposure-in-pregnancy-outcomes-from-clinical-studies-in-inflammatory-bowel-disease
#18
U Mahadevan, S Vermeire, K Lasch, B Abhyankar, F Bhayat, A Blake, M Dubinsky
BACKGROUND: Vedolizumab is a gut-selective immunoglobulin G1 monoclonal antibody to α4 β7 integrin for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Prospective clinical studies of vedolizumab in pregnancy have not been conducted; therefore, existing safety data of vedolizumab in pregnancy were examined. AIM: To assess pregnancy outcomes in females and partners of males who received vedolizumab. METHODS: All pregnancy data collected during the clinical programme (from 14 May 2007 to 27 June 2013) and in the post-marketing setting (to 19 November 2015) were analysed...
February 7, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28161290/safety-of-treatments-for-inflammatory-bowel-disease-clinical-practice-guidelines-of-the-italian-group-for-the-study-of-inflammatory-bowel-disease-ig-ibd
#19
Livia Biancone, Vito Annese, Sandro Ardizzone, Alessandro Armuzzi, Emma Calabrese, Flavio Caprioli, Fabiana Castiglione, Michele Comberlato, Mario Cottone, Silvio Danese, Marco Daperno, Renata D'Incà, Giuseppe Frieri, Walter Fries, Paolo Gionchetti, Anna Kohn, Giovanni Latella, Monica Milla, Ambrogio Orlando, Claudio Papi, Carmelina Petruzziello, Gabriele Riegler, Fernando Rizzello, Simone Saibeni, Maria Lia Scribano, Maurizio Vecchi, Piero Vernia, Gianmichele Meucci
Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs...
January 17, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28147349/leukocyte-anti-trafficking-strategies-current-status-and-future-directions
#20
REVIEW
Bruce E Sands
BACKGROUND: In inflammatory bowel diseases (IBD), a pivotal step in the initiation and perpetuation of mucosal inflammation entails the recruitment of inflammatory leukocytes to the gut. Understanding the carefully coordinated series of molecular events that culminate in the recruitment of leukocytes to the gut has resulted in novel interventions with new capabilities in treating both Crohn's disease and ulcerative colitis. Key Messages: Natalizumab, an anti-α4 integrin antibody, was the first agent to demonstrate the efficacy of this approach for the induction and maintenance of response and remission in Crohn's disease...
2017: Digestive Diseases
keyword
keyword
45192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"